Research programme: anti-CD137 monoclonal antibodies - GTC Biotherapeutics

Drug Profile

Research programme: anti-CD137 monoclonal antibodies - GTC Biotherapeutics

Alternative Names: Anti-4-1BB monoclonal antibodies - GTC; anti-CD137 monoclonal antibodies research programme - GTC Biotherapeutics

Latest Information Update: 08 Dec 2010

Price : $50

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; rEVO Biologics
  • Class Monoclonal antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
  • 10 Dec 2007 This programme is still in active development
  • 07 May 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top